AstraZeneca PLC (LON:AZN)

Market Cap	240.74B +39.5%
Revenue (ttm)	43.64B +8.6%
Net Income	7.60B +45.3%
EPS	4.86 +45.3%
Shares Out	1.55B
PE Ratio	31.94
Forward PE	20.38
Dividend	2.36 (1.56%)
Ex-Dividend Date	Feb 19, 2026

Volume	2,510,360
Average Volume	2,069,826
Open	15,174
Previous Close	15,160
Day's Range	15,174 - 15,522
52-Week Range	9,574 - 15,522
Beta	0.19
RSI	74.22
Earnings Date	Feb 10, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 94,300
• Stock Exchange: London Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.

Financial numbers in USD